What happened in peptide research this month: October 2026
Published 2026-10-29 · Covers Oct 1–29, 2026 · Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records)
This is a plain-language roundup of the month's most important peptide news. Each item links to the original record: a journal paper on PubMed, a ClinicalTrials.gov entry, a regulator's page, or, where nothing else exists yet, the company's own announcement (marked "company-reported"). This digest gives no dose information, and nothing here is medical advice.
Regulators
Europe: a CNP-based treatment for children with achondroplasia moved closer to approval. On October 15, the European Medicines Agency's medicines committee (CHMP) recommended approving Yuviwel (navepegritide) for children with achondroplasia, an inherited condition that affects bone growth. Navepegritide is a long-acting "prodrug" that slowly releases C-type natriuretic peptide (CNP), a natural signal that helps bones grow. The European Commission makes the final decision, usually within about two months.
Sources: EMA, Yuviwel · EMA CHMP highlights, Oct 12–15, 2026
Europe: the same meeting recommended Foundayo (orforglipron). It's a once-daily GLP-1 pill for type 2 diabetes and weight management. Orforglipron isn't a peptide; it's a small molecule that acts on the same GLP-1 receptor as peptide drugs like semaglutide. We include it because readers often compare the two. The committee also recommended an extended indication for Kyinsu, a combination of two peptide-based medicines (insulin icodec and semaglutide). The EMA hasn't yet published the details of that extension.
Sources: EMA, Foundayo · EMA CHMP highlights
United States: HHS issues a draft policy on compounding six peptides. On October 28, HHS released a draft, non-binding enforcement-discretion policy for 503A compounding of BPC-157, TB-500, MOTS-c, epitalon, Semax and KPV under set conditions. It is not an approval and not a final rule. Read our entry.
Source: Federal Register public inspection, FR Doc. 2026-22192
United States: FDA says retatrutide is a "drug," not a "biologic." In a letter dated October 2, filed in a federal appeals court case on October 8, the FDA concluded that retatrutide, Eli Lilly's experimental triple-hormone weekly shot, is not a biological product. That means any approval application would go through the standard drug pathway. Earlier, Lilly had said it planned to file in early 2027 as a biologic. Retatrutide is not approved anywhere.
Source: FDA letter (U.S. Court of Appeals, 7th Cir., No. 26-1301)
South Korea approves efpeglenatide for weight management. On October 7, Korea's Ministry of Food and Drug Safety approved efpeglenatide, a weekly GLP-1 shot from Hanmi Pharmaceutical, for long-term weight management in adults without diabetes. The approval rests partly on a Korean phase 3 trial whose 40-week results have so far been released only by the company: 9.75% average weight loss vs 0.95% on placebo (company-reported). Efpeglenatide is not approved in the U.S. or EU.
Sources: Hanmi stock-exchange disclosure, Oct 7 (Korean) · Hanmi interim results release
No new peptide medicines were approved by FDA's drug center in October. That's as of Oct 29, per FDA's list of novel drug approvals for 2026.
Source: FDA, Novel Drug Approvals for 2026
New peer-reviewed results
Survodutide in type 2 diabetes with excess weight (SYNCHRONIZE-2), published October 1. In this 76-week phase 3 trial of about 750 adults, counting everyone (including people who stopped treatment), people on survodutide lost about 8% to 10% of their body weight vs about 4% on placebo. Blood sugar improved. Stomach side effects were common, and 18% of people on survodutide stopped treatment because of them. Survodutide is not approved anywhere.
Sources: NEJM paper, PubMed 42820639 · ClinicalTrials.gov NCT06066528
Retatrutide and sleep apnea, published October 21. Two phase 3 substudies enrolled adults with moderate-to-severe obstructive sleep apnea and excess weight: 243 without diabetes and 448 with type 2 diabetes. They started with about 56 to 59 breathing pauses or dips per hour of sleep. After 80 weeks, the higher-dose groups had roughly 25 to 34 fewer events per hour, compared with about 10 fewer on placebo. Stomach and gut side effects were the most common. The trials were funded by Lilly. Retatrutide is not approved anywhere.
Sources: NEJM paper, PubMed 42904878 · NCT05929066 · NCT05929079
Just before October: on September 29, two larger retatrutide trials (TRIUMPH-1 in adults without diabetes, TRIUMPH-2 in adults with type 2 diabetes) and a phase 2 trial of petrelintide, an amylin-like shot (ZUPREME-1), were published. They appear in our /news/ entries.
Sources: PubMed 42814954 · PubMed 42810372 · PubMed 42810355
Conference results (not yet full papers)
Icotrokinra, an oral peptide, in psoriatic arthritis (ICONIC-PsA 1), abstract published October 20. This 552-person phase 3 trial tested icotrokinra in adults with active psoriatic arthritis. After 16 weeks, 58% of people on the lower dose had at least a 20% improvement in joint symptoms, vs 41% on placebo. The higher dose (52%) didn't clearly beat placebo. Icotrokinra is FDA-approved for plaque psoriasis (as Icotyde) but not for psoriatic arthritis. The full presentation is on November 10 at ACR Convergence.
Sources: ACR abstract LB12 · NCT06878404 · FDA Drug Trials Snapshot: Icotyde
CagriSema in women by menopause stage, posters on October 20 (company-reported). Novo Nordisk re-analyzed its earlier REDEFINE 1 trial after the fact and reported similar weight loss in women before, during and after menopause, in a scenario that assumes everyone stayed on treatment. Menopause stage was estimated afterward, and no formal test compared the groups, so the analysis can't show real differences between stages. CagriSema is not approved; an FDA decision is expected in Q4 2026, per the company.
Sources: Novo Nordisk release, Oct 20 · Original REDEFINE 1 paper, PubMed 40544433
Company announcements (not yet peer-reviewed)
Petrelintide in type 2 diabetes (ZUPREME-2), October 7. Zealand Pharma reported "up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo" in 220 adults with type 2 diabetes and excess weight. Full results are promised at a future scientific meeting.
Sources: Zealand announcement · NCT06926842
Results reported only by a company are marked Evidence Level C on our /news/ page. We hold some caution until the full paper is out and update the entry when it is.
Coming up in November (dates from primary records)
- Nov 9: survodutide heart-outcomes trial (SYNCHRONIZE-CVOT) at the American Heart Association meeting, Late-Breaking Science session. AHA program
- Nov 10: ICONIC-PsA 1 full presentation at ACR Convergence. ACR abstract
- Around Nov 23 (estimate): European Commission decision on glepaglutide (Zeydovio) for short bowel syndrome. The CHMP recommended it on Sep 17, and decisions normally follow in about 67 days. EMA, Zeydovio
- Estimated trial completion dates in November (ClinicalTrials.gov): retatrutide vs tirzepatide head-to-head (NCT06662383), tirzepatide in type 1 diabetes (NCT06914895, NCT06962280) and the apitegromab extension study (NCT05626855). Completion dates are estimates, and results usually come later.
This digest reports research and regulatory news. It is not medical advice and does not recommend any product. Talk with a licensed clinician about any treatment decision.